Clinical trials: Refractory Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders, Treatment-resistant Schizophrenia
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant schizophrenia spectrum disorder in an open trial.
- Trial name
- NCT03983018
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 9 people
- Sponsor
- Region Örebro County
Schizophrenia
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United States.
- Trial name
- NCT00250575
- Testing
- Clozapine
- Where
- 8 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Novartis
Schizophrenia
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia
This is a randomized, placebo-controlled study to assess the efficacy and safety of ATX augmentation of CLZ as a treatment for the cognitive symptoms of schizophrenia.
- Trial name
- NCT00216281
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Indiana University
Schizophrenia
Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia
m-RESIST is an m-health intervention program aimed to develop, test and evaluate a tool to allow patients suffering from treatment-resistant schizophrenia to self-manage their condition.
- Trial name
- m-RESIST (NCT03064776)
- Testing
- m-RESIST Patients, m-RESIST Caregivers
- Where
- 3 sites in Hungary, Israel and 1 more
- Volunteers
- 43 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Refractory Schizophrenia
Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia
Primary Objective: Efficacy of Occupational Therapy (OT) based Occupational Goal Intervention (OGI) in improving executive functions in patients with refractory schizophrenia as measured by the BADS.
- Trial name
- OTSchizo (NCT01879956)
- Testing
- Craft Activities, OGI Method
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Schizophrenia
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
- Trial name
- DayBreak (NCT02717195)
- Testing
- Risperidone, Olanzapine, Lu AF35700
- Where
- 147 sites in United States, Bulgaria and 12 more
- Volunteers
- 1,098 people
- Sponsor
- H. Lundbeck A/S
Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia
Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in Schizophrenia
Treatment of verbal hallucinations in schizophrenia is clinically challenging for both the patient and the therapist. For the therapist, one of the main difficulties arises from the impossibility of directly communicating with…
- Trial name
- NCT03148639
- Testing
- Avatar therapy, Treatment-as-usual
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Refractory Schizophrenia
Deep Brain Stimulation in Treatment Resistant Schizophrenia
This study aims at assessing efficacy and safety of Deep Brain Stimulation (DBS) for treatment of patients with treatment resistant schizophrenia, by means of a random, controlled and crossed study.
- Trial name
- DBS-SCHIZO (NCT02377505)
- Testing
- On-Stimulation, Off-Stimulation
- Where
- 2 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Treatment-resistant Schizophrenia
Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.
This exploratory study aims to evaluate the preliminary efficacy and safety of temporal interference (TI) stimulation in patients with treatment-resistant schizophrenia (TRS).
- Trial name
- NCT07773831
- Testing
- Temporal Interference Stimulation
- Volunteers
- 20 people
- Sponsor
- Zhimin Wang
Schizophrenia, Hallucinations, Auditory
fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations
The INTRUDE trial aims at assessing the efficacy of an fMRI-based neurofeedback procedure on drug-resistant auditory hallucinations.
- Conditions
- Schizophrenia, Hallucinations, Auditory, Hallucinations, Visual
- Trial name
- INTRUDE (NCT04798131)
- Testing
- Active neurofeedback procedure
- Where
- France
- Volunteers
- 84 people
- Sponsor
- University Hospital, Lille
Treatment-Refractory Schizophrenia
Deep Brain Stimulation for Psychosis
There are three hypotheses proposed for this study: 1) Participants will report no unanticipated serious adverse events during the eight months of treatment.
- Trial name
- NCT06257056
- Testing
- Abbott Laboratories Infinity™ implantable deep brain stimulation system
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bradley Lega
Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.
The effectiveness and efficacy of the combination of pharmacotherapy with the two new recovery-oriented programs, RECOVERYTRSGR for patients with treatment- resistant schizophrenia and RECOVERYTRSBDGR for patients with treatment…
- Trial name
- RAKGEORREC (NCT07047651)
- Testing
- Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine
- Where
- Greece
- Volunteers
- 84 people
- Sponsor
- Dr. Stavroula Rakitzi
Schizophrenia
Famotidine in Schizophrenia
Objective of the trial is to study if famotidine add-on treatment is more effective than placebo add-on in reducing symptoms of schizophrenia among patients receiving insufficient response to ongoing antipsychotic treatment.
- Trial name
- NCT01946295
- Testing
- Famotidine
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 140 people
- Sponsor
- Jesper Ekelund
Refractory Auditory Hallucinations, Schizophrenia
RTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography
This study is an before-after study in the same patient, which enrolled 36 psychiatric patients with refractory auditory hallucinations.
- Trial name
- NCT06802939
- Testing
- rTMS
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Efficacy of tACS for Treatment of Auditory Hallucinations in Refractory Schizophrenia
The aim of this study is to evaluate the feasibility and efficacy of transcranial alternating current stimulation (tACS) as an add-on treatment for auditory hallucinations in refractory schizophrenia.
- Trial name
- NCT05282329
- Testing
- Transcranial alternating Current Stimulation (tACS)-active
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Anding Hospital
Schizophrenia, Treatment Resistant Schizophrenia
Effectiveness of Exercise Alone and tDCS+Exercise on Cognitive Function Improvement in Patients With Treatment Resistant Schizophrenia
Cognitive impairment is a major determinant of disability in schizophrenia. Aerobic exercise improves global cognition in schizophrenia, particularly working memory and attention/vigilance.
- Conditions
- Schizophrenia, Treatment Resistant Schizophrenia, Cognitive Impairment
- Trial name
- TRACE (NCT07404319)
- Testing
- Aerobic Exercise, Stretching/Education Control, Active tDCS
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- Kit Wa Chan
Schizophrenia
DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia
Pharmacotherapy for schizophrenia has limitations such as residual positive and negative symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia is still a difficult clinical issue at present.
- Trial name
- NCT02532686
- Testing
- DAAOI-2
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation to Clozapine
The proposed pilot study will compare minocycline augmentation with clozapine in individuals with high vs low inflammation as measured by CRP.
- Trial name
- NCT02124811
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Refractory Schizophrenia
Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory Schizophrenia
Schizophrenia is a lifelong psychiatric disorder with a prevalence rate of 0.559% and a lifetime prevalence rate of 0.588% among Chinese adults.
- Trial name
- NCT07369401
- Testing
- Deep Brain Stimulation
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Deep Brain Stimulation
Efficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders
This is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of combo-stim deep brain stimulation for treatment-refractory mental disorders (obsessive-compulsive disorder…
- Trial name
- NCT06112067
- Testing
- deep brain stimulation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Mental Health Center